Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Articles|April 20, 2021
Rheumatoid Arthritis Quiz: Principles of Treat-to-Target
Author(s)Ingrid Torjesen
A treat-to-target strategy is recommended by the American College of Rheumatology for managing rheumatoid arthritis patients over a non-targeted approach. Test your knowledge of the rationale for treat-to target and how it should be implemented in our quiz.
Advertisement
Which is the most important consideration when treating rheumatoid arthritis?
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement